Denmark· DK-28105605715
Qarziba
A dinutuximab beta product containing dinutuximab beta, registered in Denmark by Recordati Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Dinutuximab beta is registered in 11 of 19 countries.
Countries holding a registration under ATC L01FX06 (dinutuximab beta), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 7 of them publish a price we can compare per daily dose
Dinutuximab beta · ATC L01FX06
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- dinutuximab beta
- Manufacturer
- Recordati Netherlands B.V.
- Country
- Denmark (DK)
- ATC code
- L01FX06
- ATC class
- Dinutuximab beta
- Defined daily dose
- 2.6 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105605715
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
183 interactions on record for dinutuximab beta.
Graded by severity as the source publishes them — 54 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dinutuximab beta · interactions on record
183 records
- 54 severe
- 129 moderate
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01FX06
Dinutuximab beta, as other registers publish it.
- FinlandQarzibaRecordati Netherlands B.V.
- NorwayQarzibaRecordati Netherlands B.V.
- PolandQarzibaRecordati Netherlands B.V.
- IcelandQarzibaRecordati Netherlands B.V.
- FinlandQarzibaAbacus Medicine A/S
- CzechiaQARZIBARecordati Netherlands B.V., Schiphol-Rijk
- SwitzerlandQarziba 20,25 mg/4,5 ml, Konzentrat zur Herstellung einer InfusionslösungMedius AG
- United KingdomQarziba 20mg/4.5ml concentrate for solution for infusion vialsRecordati UK Ltd
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b5a16512-3607-48bf-8ea6-11302b811bd3 GET /v1/drugs/b5a16512-3607-48bf-8ea6-11302b811bd3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "4,5 mg/ml",
"auth_role": "CO-RAP",
"dk_drugid": "28105605715",
"substance": "dinutuximab beta",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "42863"
}See everything about dinutuximab beta.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.